Download Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Therapeutic Drug Monitoring Market: By Drug Type, By Technology and Region Forecast 2020-2031
Therapeutic Drug Monitoring Market: By Drug Type, By Technology and Region Forecast 2020-2031
Therapeutic Drug Monitoring Market size was valued at US$ 2.3 billion in 2024 and is expected to reach US$ 4.1 billion by 2031, growing at a significant CAGR of 8.4% from 2025-2031. Therapeutic Drug Monitoring is a measurement of drug concentrations or drug metabolites in plasma. It is usually carried out for narrow therapeutic index drugs. Therapeutic drug monitoring is the clinical assessment of drug’s pharmacokinetic properties. TDM helps in reducing drug toxicity, enhance drug efficacy and diagnostic purpose. Various drug molecules usually monitored at clinical practice. For example: drugs like digoxin, cyclosporin, phenytoin, carbamazepine and valproic acid, among others. Immunosuppressant drugs mostly used in the organ transplantation cases. Patients using ISD’s commonly undergo TDM owing to their narrow therapeutic index, variability in blood concentrations between individuals and severe adverse effects.
Based on the drug type, antipsychotic segment dominates the global therapeutic drug monitoring market. Among the antipsychotics, haloperidol is highly preferred for TDM due to severe adverse effects with the drug. However, the prescription rate for the drug is decreasing compared with newer atypical antipsychotics. In Asia pacific region, China and Japan accounted for the highest market share in 2022. Typical antipsychotics such as Clozapine, Olanzapine, and Risperidone are frequently preferred for TDM due to large interpatient variability in plasma. Generally, LC-MS/MS is commonly preferred for the TDM followed by immunoassay and other LC techniques. Moreover, the TDM for Lithium is also highly preferred because of the narrow therapeutic range, unpredictable serum concentrations, and concentration-dependent toxicity and chromatographic techniques such as LC-MS and HPLC are preferred for the assay.
Study Period
2025-2031Base Year
2024CAGR
8.4%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
Due to a surge in the number of chronic diseases such as cancer, cardiovascular, and neurological disorders. Moreover, the rise in R&D activities for the development of new test kits, the rise in the adoption of therapeutic drug monitoring in emerging countries, and development in healthcare infrastructure is anticipated to propel the global therapeutic drug monitoring market over the forecast years.
North America accounted for a larger revenue share of 54.5% and accounted for 612.8 Million in the global therapeutic drug monitoring market with 4.6% CAGR. An increase in the adoption of therapeutic drug assays by healthcare professionals, innovation of advanced test kits by the market players, high number of prescriptions, and surge in prevalence of chronic diseases are boosting the growth of the market in the region. Asia Pacific market projected to grow at significant rate owing to increase in number of patients with chronic diseases in India, China, and Japan, development in healthcare infrastructure, and launch of newer test kits into market are expected to enhance the market over the forecast timeframe.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 2.3 billion |
|
Market Size in 2031 |
US$ 4.1 billion |
|
Market CAGR |
8.4% |
|
By Drug Type |
|
|
By Technology |
|
|
By Region |
|
Download Free Sample Report
Therapeutic drug monitoring market size was valued at US$ 2.3 billion in 2024 and is expected to reach US$ 4.1 billion by 2031, growing at a significant CAGR of 8.4%.
The top TDM drug classes are Antidepressants (17.9%), Immunosuppressants (14.3%), Hormones (13.2%), Analgesics (10.4%), and Antiepileptics (9%)
LC-MS/MS segment dominates the therapeutic drug monitoring market in terms of both value and volume.
North America (USA) and Europe (Germany and UK) are the potential markets in the therapeutic drug monitoring market.
| 1.Executive Summary |
| 2.Global Therapeutic Drug Monitoring Market Introduction |
| 2.1.Global Therapeutic Drug Monitoring Market - Taxonomy |
| 2.2.Global Therapeutic Drug Monitoring Market - Definitions |
| 2.2.1. By Drug Type |
| 2.2.2. By Technology |
| 2.2.3. By Region |
| 3.Global Therapeutic Drug Monitoring Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Therapeutic Drug Monitoring Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Therapeutic Drug Monitoring Market By Drug Type , 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 5.1. Antibiotics (Chloramphenicol, Linezolid, Piperacillin/Tazobactam, Rifampicin, Vancomycin, Gentamicin, Amikacin, Tobramycin, Teicoplanin, Ceftazidime, Meropenem, Nafcillin, Ticarcillin) |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Addiction Therapeutics (Buprenorphine, Methadone, Naltrexone, Tapentadol) |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Analgesic (Paracetamol, Ibuprofen, Naproxen, Aspirin, Tramadol) |
| 5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Anticancer Drugs (5-Fluorouracil, Docetaxel, Methotrexate, Paclitaxel, Imatinib, Busulfan) |
| 5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Alzheimer Disease (Donepezil, Galantamine, Memantine) |
| 5.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Analeptics (Caffeine, Theophylline) |
| 5.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Antiarrhythmic Drugs (Amiodarone, Digoxin, Flecainide, Mexiletine, Verapamil, Digitoxin, Lidocaine) |
| 5.7.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 5.8. Anticoagulants (Dabigatran Warfarin) |
| 5.8.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 5.9. Antihypertensives (Propranolol) |
| 5.9.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.9.3. Market Opportunity Analysis |
| 5.10. Antidepressants (Citalopram, Fluoxetine, Fluvoxamine, Sertraline, Venlafaxine, Trazodone, Protriptyline, Nortriptyline, Imipramine, Desipramine, Doxepin, Clomipramine, Bupropion, Amitryptiline) |
| 5.10.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.10.3. Market Opportunity Analysis |
| 5.11. Antiepileptics (Ethosuximide, Felbamate, Gabapentin, Lamotrigine, Pregabaline, Topiramate, Zonisamide, Carbamazepine, Valproic Acid, Lacosamide, Levetiracetam, Phenobarbital, Phenytoin) |
| 5.11.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.11.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.11.3. Market Opportunity Analysis |
| 5.12. Anti-HIV Drugs (Atazanavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Darunavir, Fosamprenavir, Tipranavir, Efavirenz, Etravirine, Nevirapine, Rilpivirine) |
| 5.12.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.12.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.12.3. Market Opportunity Analysis |
| 5.13. Antipsychotics (Aripiprazole, Clozapine, Haloperidol, Olanzapine, Ziprasidone, Chlorpromazine, Lithium, Lurasidone, Paliperidone, Perphenazine, Quetiapine, Risperidone, Thiothixene) |
| 5.13.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.13.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.13.3. Market Opportunity Analysis |
| 5.14. Hormones (T3, T4, TSH) |
| 5.14.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.14.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.14.3. Market Opportunity Analysis |
| 5.15. Immunosuppressants (Cyclosporin A, Everolimus, Mycophenolic acid, Sirolimus, Tacrolimus) |
| 5.15.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.15.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.15.3. Market Opportunity Analysis |
| 5.16. Antifungals (Fluconazole, Itraconazole, Voriconazole, Posaconazole, Anidulafungin, Ketoconazole) |
| 5.16.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.16.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.16.3. Market Opportunity Analysis |
| 6.Global Therapeutic Drug Monitoring Market By Technology, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 6.1. Immuno- Assay, |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Mass Spectrometry, |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. GC-MS/MS, |
| 6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Others |
| 6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7.Global Therapeutic Drug Monitoring Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Therapeutic Drug Monitoring Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 8.1. Drug Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Antibiotics (Chloramphenicol, Linezolid, Piperacillin/Tazobactam, Rifampicin, Vancomycin, Gentamicin, Amikacin, Tobramycin, Teicoplanin, Ceftazidime, Meropenem, Nafcillin, Ticarcillin) |
| 8.1.2.Addiction Therapeutics (Buprenorphine, Methadone, Naltrexone, Tapentadol) |
| 8.1.3.Analgesic (Paracetamol, Ibuprofen, Naproxen, Aspirin, Tramadol) |
| 8.1.4.Anticancer Drugs (5-Fluorouracil, Docetaxel, Methotrexate, Paclitaxel, Imatinib, Busulfan) |
| 8.1.5.Alzheimer Disease (Donepezil, Galantamine, Memantine) |
| 8.1.6.Analeptics (Caffeine, Theophylline) |
| 8.1.7.Antiarrhythmic Drugs (Amiodarone, Digoxin, Flecainide, Mexiletine, Verapamil, Digitoxin, Lidocaine) |
| 8.1.8.Anticoagulants (Dabigatran Warfarin) |
| 8.1.9.Antihypertensives (Propranolol) |
| 8.1.10.Antidepressants (Citalopram, Fluoxetine, Fluvoxamine, Sertraline, Venlafaxine, Trazodone, Protriptyline, Nortriptyline, Imipramine, Desipramine, Doxepin, Clomipramine, Bupropion, Amitryptiline) |
| 8.1.11.Antiepileptics (Ethosuximide, Felbamate, Gabapentin, Lamotrigine, Pregabaline, Topiramate, Zonisamide, Carbamazepine, Valproic Acid, Lacosamide, Levetiracetam, Phenobarbital, Phenytoin) |
| 8.1.12.Anti-HIV Drugs (Atazanavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Darunavir, Fosamprenavir, Tipranavir, Efavirenz, Etravirine, Nevirapine, Rilpivirine) |
| 8.1.13.Antipsychotics (Aripiprazole, Clozapine, Haloperidol, Olanzapine, Ziprasidone, Chlorpromazine, Lithium, Lurasidone, Paliperidone, Perphenazine, Quetiapine, Risperidone, Thiothixene) |
| 8.1.14.Hormones (T3, T4, TSH) |
| 8.1.15.Immunosuppressants (Cyclosporin A, Everolimus, Mycophenolic acid, Sirolimus, Tacrolimus) |
| 8.1.16.Antifungals (Fluconazole, Itraconazole, Voriconazole, Posaconazole, Anidulafungin, Ketoconazole) |
| 8.2. Technology Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Immuno- Assay, |
| 8.2.2.Mass Spectrometry, |
| 8.2.3.GC-MS/MS, |
| 8.2.4.Others |
| 8.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Therapeutic Drug Monitoring Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 9.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Antibiotics (Chloramphenicol, Linezolid, Piperacillin/Tazobactam, Rifampicin, Vancomycin, Gentamicin, Amikacin, Tobramycin, Teicoplanin, Ceftazidime, Meropenem, Nafcillin, Ticarcillin) |
| 9.1.2.Addiction Therapeutics (Buprenorphine, Methadone, Naltrexone, Tapentadol) |
| 9.1.3.Analgesic (Paracetamol, Ibuprofen, Naproxen, Aspirin, Tramadol) |
| 9.1.4.Anticancer Drugs (5-Fluorouracil, Docetaxel, Methotrexate, Paclitaxel, Imatinib, Busulfan) |
| 9.1.5.Alzheimer Disease (Donepezil, Galantamine, Memantine) |
| 9.1.6.Analeptics (Caffeine, Theophylline) |
| 9.1.7.Antiarrhythmic Drugs (Amiodarone, Digoxin, Flecainide, Mexiletine, Verapamil, Digitoxin, Lidocaine) |
| 9.1.8.Anticoagulants (Dabigatran Warfarin) |
| 9.1.9.Antihypertensives (Propranolol) |
| 9.1.10.Antidepressants (Citalopram, Fluoxetine, Fluvoxamine, Sertraline, Venlafaxine, Trazodone, Protriptyline, Nortriptyline, Imipramine, Desipramine, Doxepin, Clomipramine, Bupropion, Amitryptiline) |
| 9.1.11.Antiepileptics (Ethosuximide, Felbamate, Gabapentin, Lamotrigine, Pregabaline, Topiramate, Zonisamide, Carbamazepine, Valproic Acid, Lacosamide, Levetiracetam, Phenobarbital, Phenytoin) |
| 9.1.12.Anti-HIV Drugs (Atazanavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Darunavir, Fosamprenavir, Tipranavir, Efavirenz, Etravirine, Nevirapine, Rilpivirine) |
| 9.1.13.Antipsychotics (Aripiprazole, Clozapine, Haloperidol, Olanzapine, Ziprasidone, Chlorpromazine, Lithium, Lurasidone, Paliperidone, Perphenazine, Quetiapine, Risperidone, Thiothixene) |
| 9.1.14.Hormones (T3, T4, TSH) |
| 9.1.15.Immunosuppressants (Cyclosporin A, Everolimus, Mycophenolic acid, Sirolimus, Tacrolimus) |
| 9.1.16.Antifungals (Fluconazole, Itraconazole, Voriconazole, Posaconazole, Anidulafungin, Ketoconazole) |
| 9.2. Technology Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Immuno- Assay, |
| 9.2.2.Mass Spectrometry, |
| 9.2.3.GC-MS/MS, |
| 9.2.4.Others |
| 9.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 10.Asia Pacific (APAC) Therapeutic Drug Monitoring Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 10.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Antibiotics (Chloramphenicol, Linezolid, Piperacillin/Tazobactam, Rifampicin, Vancomycin, Gentamicin, Amikacin, Tobramycin, Teicoplanin, Ceftazidime, Meropenem, Nafcillin, Ticarcillin) |
| 10.1.2.Addiction Therapeutics (Buprenorphine, Methadone, Naltrexone, Tapentadol) |
| 10.1.3.Analgesic (Paracetamol, Ibuprofen, Naproxen, Aspirin, Tramadol) |
| 10.1.4.Anticancer Drugs (5-Fluorouracil, Docetaxel, Methotrexate, Paclitaxel, Imatinib, Busulfan) |
| 10.1.5.Alzheimer Disease (Donepezil, Galantamine, Memantine) |
| 10.1.6.Analeptics (Caffeine, Theophylline) |
| 10.1.7.Antiarrhythmic Drugs (Amiodarone, Digoxin, Flecainide, Mexiletine, Verapamil, Digitoxin, Lidocaine) |
| 10.1.8.Anticoagulants (Dabigatran Warfarin) |
| 10.1.9.Antihypertensives (Propranolol) |
| 10.1.10.Antidepressants (Citalopram, Fluoxetine, Fluvoxamine, Sertraline, Venlafaxine, Trazodone, Protriptyline, Nortriptyline, Imipramine, Desipramine, Doxepin, Clomipramine, Bupropion, Amitryptiline) |
| 10.1.11.Antiepileptics (Ethosuximide, Felbamate, Gabapentin, Lamotrigine, Pregabaline, Topiramate, Zonisamide, Carbamazepine, Valproic Acid, Lacosamide, Levetiracetam, Phenobarbital, Phenytoin) |
| 10.1.12.Anti-HIV Drugs (Atazanavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Darunavir, Fosamprenavir, Tipranavir, Efavirenz, Etravirine, Nevirapine, Rilpivirine) |
| 10.1.13.Antipsychotics (Aripiprazole, Clozapine, Haloperidol, Olanzapine, Ziprasidone, Chlorpromazine, Lithium, Lurasidone, Paliperidone, Perphenazine, Quetiapine, Risperidone, Thiothixene) |
| 10.1.14.Hormones (T3, T4, TSH) |
| 10.1.15.Immunosuppressants (Cyclosporin A, Everolimus, Mycophenolic acid, Sirolimus, Tacrolimus) |
| 10.1.16.Antifungals (Fluconazole, Itraconazole, Voriconazole, Posaconazole, Anidulafungin, Ketoconazole) |
| 10.2. Technology Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Immuno- Assay, |
| 10.2.2.Mass Spectrometry, |
| 10.2.3.GC-MS/MS, |
| 10.2.4.Others |
| 10.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Therapeutic Drug Monitoring Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 11.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Antibiotics (Chloramphenicol, Linezolid, Piperacillin/Tazobactam, Rifampicin, Vancomycin, Gentamicin, Amikacin, Tobramycin, Teicoplanin, Ceftazidime, Meropenem, Nafcillin, Ticarcillin) |
| 11.1.2.Addiction Therapeutics (Buprenorphine, Methadone, Naltrexone, Tapentadol) |
| 11.1.3.Analgesic (Paracetamol, Ibuprofen, Naproxen, Aspirin, Tramadol) |
| 11.1.4.Anticancer Drugs (5-Fluorouracil, Docetaxel, Methotrexate, Paclitaxel, Imatinib, Busulfan) |
| 11.1.5.Alzheimer Disease (Donepezil, Galantamine, Memantine) |
| 11.1.6.Analeptics (Caffeine, Theophylline) |
| 11.1.7.Antiarrhythmic Drugs (Amiodarone, Digoxin, Flecainide, Mexiletine, Verapamil, Digitoxin, Lidocaine) |
| 11.1.8.Anticoagulants (Dabigatran Warfarin) |
| 11.1.9.Antihypertensives (Propranolol) |
| 11.1.10.Antidepressants (Citalopram, Fluoxetine, Fluvoxamine, Sertraline, Venlafaxine, Trazodone, Protriptyline, Nortriptyline, Imipramine, Desipramine, Doxepin, Clomipramine, Bupropion, Amitryptiline) |
| 11.1.11.Antiepileptics (Ethosuximide, Felbamate, Gabapentin, Lamotrigine, Pregabaline, Topiramate, Zonisamide, Carbamazepine, Valproic Acid, Lacosamide, Levetiracetam, Phenobarbital, Phenytoin) |
| 11.1.12.Anti-HIV Drugs (Atazanavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Darunavir, Fosamprenavir, Tipranavir, Efavirenz, Etravirine, Nevirapine, Rilpivirine) |
| 11.1.13.Antipsychotics (Aripiprazole, Clozapine, Haloperidol, Olanzapine, Ziprasidone, Chlorpromazine, Lithium, Lurasidone, Paliperidone, Perphenazine, Quetiapine, Risperidone, Thiothixene) |
| 11.1.14.Hormones (T3, T4, TSH) |
| 11.1.15.Immunosuppressants (Cyclosporin A, Everolimus, Mycophenolic acid, Sirolimus, Tacrolimus) |
| 11.1.16.Antifungals (Fluconazole, Itraconazole, Voriconazole, Posaconazole, Anidulafungin, Ketoconazole) |
| 11.2. Technology Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Immuno- Assay, |
| 11.2.2.Mass Spectrometry, |
| 11.2.3.GC-MS/MS, |
| 11.2.4.Others |
| 11.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Therapeutic Drug Monitoring Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 12.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Antibiotics (Chloramphenicol, Linezolid, Piperacillin/Tazobactam, Rifampicin, Vancomycin, Gentamicin, Amikacin, Tobramycin, Teicoplanin, Ceftazidime, Meropenem, Nafcillin, Ticarcillin) |
| 12.1.2.Addiction Therapeutics (Buprenorphine, Methadone, Naltrexone, Tapentadol) |
| 12.1.3.Analgesic (Paracetamol, Ibuprofen, Naproxen, Aspirin, Tramadol) |
| 12.1.4.Anticancer Drugs (5-Fluorouracil, Docetaxel, Methotrexate, Paclitaxel, Imatinib, Busulfan) |
| 12.1.5.Alzheimer Disease (Donepezil, Galantamine, Memantine) |
| 12.1.6.Analeptics (Caffeine, Theophylline) |
| 12.1.7.Antiarrhythmic Drugs (Amiodarone, Digoxin, Flecainide, Mexiletine, Verapamil, Digitoxin, Lidocaine) |
| 12.1.8.Anticoagulants (Dabigatran Warfarin) |
| 12.1.9.Antihypertensives (Propranolol) |
| 12.1.10.Antidepressants (Citalopram, Fluoxetine, Fluvoxamine, Sertraline, Venlafaxine, Trazodone, Protriptyline, Nortriptyline, Imipramine, Desipramine, Doxepin, Clomipramine, Bupropion, Amitryptiline) |
| 12.1.11.Antiepileptics (Ethosuximide, Felbamate, Gabapentin, Lamotrigine, Pregabaline, Topiramate, Zonisamide, Carbamazepine, Valproic Acid, Lacosamide, Levetiracetam, Phenobarbital, Phenytoin) |
| 12.1.12.Anti-HIV Drugs (Atazanavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Darunavir, Fosamprenavir, Tipranavir, Efavirenz, Etravirine, Nevirapine, Rilpivirine) |
| 12.1.13.Antipsychotics (Aripiprazole, Clozapine, Haloperidol, Olanzapine, Ziprasidone, Chlorpromazine, Lithium, Lurasidone, Paliperidone, Perphenazine, Quetiapine, Risperidone, Thiothixene) |
| 12.1.14.Hormones (T3, T4, TSH) |
| 12.1.15.Immunosuppressants (Cyclosporin A, Everolimus, Mycophenolic acid, Sirolimus, Tacrolimus) |
| 12.1.16.Antifungals (Fluconazole, Itraconazole, Voriconazole, Posaconazole, Anidulafungin, Ketoconazole) |
| 12.2. Technology Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Immuno- Assay, |
| 12.2.2.Mass Spectrometry, |
| 12.2.3.GC-MS/MS, |
| 12.2.4.Others |
| 12.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.ARK Diagnostics, Inc. |
| 13.2.2.Beckman Coulter |
| 13.2.3.Ortho Clinical Diagnostics |
| 13.2.4.Sekisui Diagnostics |
| 13.2.5.SJK Global, LLC |
| 13.2.6.Chromsystems |
| 13.2.7.Meridian Healthcare S.R.L. |
| 13.2.8.Randox Laboratories Ltd |
| 13.2.9.Sekisui Medical Co. Ltd. |
| 13.2.10.Thermo Fisher Scientific |
| 13.2.11.North American Science Associates, Inc. |
| 13.2.12.Ortho Clinical Diagnostics, Randox Laboratories Ltd |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.